Oh, what a time to be alive! In the groundbreaking world of medical research, we’ve stumbled upon a riveting discovery: the brain arteriovenous malformation (BAVM) nidus compactness score (CS), a dazzling metric derived from the mystical art of angiography. This revolutionary score, akin to grading avocados at the supermarket, predicts BAVM recurrence after surgical resection in children with sporadic BAVMs. But wait, there’s more! We’ve now ventured into the uncharted territory of children with hereditary hemorrhagic telangiectasia (HHT) to see how their BAVMs stack up on this compactness scale.

In a thrilling saga of medical detective work, a pediatric interventional neuroradiologist donned their Sherlock Holmes cap and reviewed angiograms to determine the CS of BAVMs in these special children. The CS, a measure of how snugly packed the overall nidus and perinidal anomalous vessels are, comes in three exciting flavors: 1 = diffuse (think of a loosely organized flash mob), 2 = intermediate (a somewhat organized queue), and 3 = compact (sardines in a can).

Out of 78 children with HHT and brain vascular malformations, 48 had a conventional angiogram, and 47 of these angiograms were actually available for review (because apparently, angiograms can play hide and seek). In these 47 children, 54 BAVMs were identified, showcasing a variety of compactness scores: 13% were playing it loose (CS=1), 53.7% were fence-sitters (CS=2), and 33.3% were tight-knit (CS=3). This was a stark contrast to the previously reported children with sporadic BAVMs, where the scores were more spread out, making one ponder the mysteries of BAVM compactness.

Among the HHT crowd, seven children experienced intracranial hemorrhage, with a distribution across the CS spectrum, suggesting that when it comes to brain bleeds, compactness might play a role, but it’s still anyone’s guess.

The conclusion? A range of CS exists across HHT BAVMs, hinting that this could be an angiographic measure of interest for future studies. Because, obviously, what we need is more research to determine whether this score is the crystal ball that predicts hemorrhage risk or post-surgical recurrence risk in HHT-associated BAVMs. This could, potentially, one day, maybe, be used to direct BAVM treatment. Because if there’s one thing we know, it’s that in the world of medical research, the journey is never over, and the quest for answers continues ad infinitum.